Daito Pharmaceutical Co.,Ltd.
4577.T · JPX
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Revenue | ¥13,011,000 | ¥14,034,000 | ¥12,025,000 | ¥11,906,000 |
| % Growth | -7.3% | 16.7% | 1% | – |
| Cost of Goods Sold | ¥10,453,000 | ¥11,772,000 | ¥10,028,000 | ¥9,777,000 |
| Gross Profit | ¥2,558,000 | ¥2,262,000 | ¥1,997,000 | ¥2,129,000 |
| % Margin | 19.7% | 16.1% | 16.6% | 17.9% |
| R&D Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥1,558,000 | ¥1,510,000 | ¥1,600,000 | ¥1,507,000 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥2,000 | ¥0 | ¥0 | ¥0 |
| Operating Expenses | ¥1,560,000 | ¥1,510,000 | ¥1,600,000 | ¥1,507,000 |
| Operating Income | ¥998,000 | ¥752,000 | ¥397,000 | ¥622,000 |
| % Margin | 7.7% | 5.4% | 3.3% | 5.2% |
| Other Income/Exp. Net | ¥54,000 | -¥203,000 | ¥133,000 | -¥135,000 |
| Pre-Tax Income | ¥1,052,000 | ¥549,000 | ¥530,000 | ¥487,000 |
| Tax Expense | ¥376,000 | -¥127,000 | ¥158,000 | ¥247,000 |
| Net Income | ¥696,000 | ¥691,000 | ¥309,000 | ¥291,000 |
| % Margin | 5.3% | 4.9% | 2.6% | 2.4% |
| EPS | 23.21 | 22.71 | 20.33 | 18.96 |
| % Growth | 2.2% | 11.7% | 7.2% | – |
| EPS Diluted | 23.21 | 22.71 | 20.33 | 18.96 |
| Weighted Avg Shares Out | 29,986 | 30,422 | 15,201 | 15,293 |
| Weighted Avg Shares Out Dil | 29,986 | 30,422 | 15,201 | 15,293 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥0 | ¥1,000 | ¥0 | ¥0 |
| Interest Expense | ¥30,000 | ¥38,000 | ¥34,000 | ¥34,000 |
| Depreciation & Amortization | ¥1,083,000 | ¥1,124,000 | ¥1,105,000 | ¥1,051,500 |
| EBITDA | ¥2,083,000 | ¥1,697,000 | ¥1,668,000 | ¥1,673,500 |
| % Margin | 16% | 12.1% | 13.9% | 14.1% |